Support for 3 Seoul Biotech Startups' Global Competence and U.S. Market Expansion

Global accelerator and TIPS operator Genaxis has successfully concluded the 'Boston Bio Cluster Global Licensing Out Program (GGAP)' in collaboration with Seoul Bio Hub, aimed at the successful entry of promising domestic bio startups into the US Boston market. This program targeted startups in the bio, pharmaceutical, medical device, and digital healthcare sectors within 10 years of establishment in Seoul, focusing on strengthening their capabilities for licensing out (L/O) into the US Boston market and attracting overseas investment. As an implementing agency for the licensing out sector, Genaxis partnered with three innovative companies: VS Pharmtech, which enhances the effectiveness of radiation therapy; JD Biosciences, a developer of small molecule compound-based metabolic disease therapeutics; and Qgenetics, a company developing synthetic new drugs for osteoporosis and obesity treatment. From November of last year to March of this year, after conducting global competency enhancement training and expert consulting domestically, an on-site program followed in Boston, USA, to verify actual licensing out strategies and explore potential partnering opportunities. Notably, incumbent pharmaceutical business development (BD) managers participated as experts, providing in-depth analysis from market positioning to contract terms for participating companies, and supporting the establishment of long-term L/O strategies from a licensee's perspective, which received high praise. In Boston, a total of 11 partnering meetings with pharmaceutical companies and investors, and 3 non-face-to-face meetings with global pharmaceutical companies were successfully arranged. Practical seminars on pitching strategies, legal aspects, regulations, and clinical design further enhanced the capabilities of the participating companies. Even after the program concluded, information on over 50 potential partner companies and global conference participation tickets were provided to each company, focusing on building a foundation for continuous global collaboration. Genaxis CEO Sohn Mi-kyung emphasized that "licensing out is a realistic means for companies to secure self-sufficiency amidst economic recession and investment drought," and stated, "Based on the high satisfaction level of this program, we will actively support participating companies by continuously advancing and planning new ideas to strengthen their L/O capabilities and lead to actual contract signings." As a private investment-centric global accelerator and TIPS operator, Genaxis consistently helps discover and nurture promising startups in ultra-gap and deep-tech sectors, including bio.